PANDAS Clinical Trial
Official title:
Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS): Clinical Characterization and Prospective Course
This study is a brief (3 month) longitudinal study following children between the ages of 4-16 years old who have been diagnosed with Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS). Parents and children (who are at a 2nd grade reading level) will complete questionnaires online or in person weekly for 3 months. Additionally, parents will track their child's symptoms 3 times/week using a mobile application for 3 months. The investigators are hoping to begin to characterize the longitudinal trajectory of neuropsychiatric symptoms in children with PANS. Additionally, the study will seek to identify baseline demographic and clinical characteristics (e.g., gender, recent onset versus chronic course, GAS versus other triggers) that predict severity of baseline neuropsychiatric symptoms and predict change in symptoms over time.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04015596 -
Trial of Naproxen Sodium for the Treatment of OCD in Children With PANDAS
|
Phase 4 | |
Completed |
NCT01617083 -
Antibiotic Treatment Trial for the PANDAS/PANS Phenotype
|
Phase 2 | |
Recruiting |
NCT02889016 -
Neurobiologic, Immunologic, and Rheumatologic Markers in Youth With PANS
|
N/A | |
Completed |
NCT02190292 -
PANS - A Detailed Study of the Patients, Their Symptoms, Biomarkers and Treatment Offered in a Scandinavian Cohort
|
||
Withdrawn |
NCT01769027 -
Antibiotic Treatment and Intravenous Immunoglobulin Trial for PANDAS
|
Phase 2 | |
Completed |
NCT01281969 -
Intravenous Immunoglobulin for PANDAS
|
Phase 3 |